Articles by Our Team

Model Answers’ scientists have diverse backgrounds and a wide range of experience across multiple therapeutic areas. They regularly publish academic work related to pharmacometrics, drug development and clinical practice.

Recent articles by our team:

Evaluation of Concomitant Antiretrovirals and CYP2C9/ CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine

Bruce Green, Herta Crawls, Thomas N. Kakuda, Simon Vanveggel, Anne Brochot


Impact of Concomitant Antiretrovirals, and CYP2C9 and CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine

Bruce Green, Herta Crauwels, Thomas N. Kakuda, Simon Vanveggel, Magda Opsomer, Anne Brochot


 

Population Pharmacokinetics of Bedaquiline(TMC207), a Novel Antituberculosis Drug

Sarah C. McLeay, Peter Vis, Rolf P. G. van Heeswijk and Bruce Green


Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial: a rebuttal

J. P. Patel, B. Green, R. K. Patel, J. G. Davies, R. Arya


Population pharmacokinetic characterisation of BAY 81-8973, a full-length recombinant factor VIII:  lessons learned – importance of including samples with factors VIII levels below the quantitation limit.  Haemophilia. 2017

Garmann D, McLeay S, Shah A, Vis P, Maas Enriquez M, Ploeger BA

What is the best size descriptor to use for pharmacokinetic studies in the obese?

Bruce Green and Stephen B Duffull


Dosing in Obesity: A Simple Solution to a Big Problem

P Y Han, S B Duffull, C M J Kirkpatrick and B Green


Development of a dosing strategy for enoxaparin in obese patients

Bruce Green andStephen B. Duffull


The Relationship between Drug Clearance and Body Size

Sarah C. McLeay, Glynn A. Morrish, Carl M. J. Kirkpatrick, Bruce Green


The effects of obesity on drug pharmacokinetics in humans

Glynn A Morrish , Manjunath P Pai & Bruce Green

Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-Naïve Patients

Giovanni Di Perri, Bruce Green, Glynn Morrish, Andrew Hill, Gerd Faetkenheuer, Markus Bickel, Yvon van Delft, Michael Kurowski & Thomas Kakuda


A Pharmacokinetic-pharmacodynamic Model for the Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100

N. A. Lack BSc, B. Green MSc, DPh, D. C. Dale MD, G. B. Calandra MD, PhD, H. Lee MD, PhD, R. T. MacFarland PhD, K. Badel BScN, W. C. Liles MD, PhD, G. Bridger PhD


Pharmacokinetic and Pharmacodynamic Modeling of the Relationship Between TAK-442 Exposure and Clinical Outcome In Patients Undergoing Elective Knee Arthroplasty

Fran Stringer, Bart Ploeger, Nolan Wood, Patrick Moneuse, Masaki Kawamura, Stuart Kupfer, Jeff Spaeder, Graham Scott

Population Pharmacokinetics of Rabeprazole and Dosing Recommendations for the Treatment of Gastroesophageal Reflux Disease in Children Aged 1–11 Years

Sarah C. McLeay , Bruce Green, William Treem, An Thyssen, Erik Mannaert, Holly Kimko


Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO

Thomas N. Kakuda PharmD, Anne Brochot MSc, Bruce Green PhD, Steven Nijs MSc, Peter Vis MSc, Magda Opsomer MD, Frank L. Tomaka MD, Richard M. W. Hoetelmans PhD

A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar

Frances Stringer, Joost DeJongh PhD, Graham Scott PhD, Meindert Danhof PharmD, PhD


The Impact of Pharmacogenomics Research on Drug Development

Shyh-Yuh Liou, Fran Stringer, Masashi Hirayama

Romiplostim Dose Response in Patients With Immune Thrombocytopenia

Dr J. J. Perez-Ruixo PhD, PharmD, Dr B. Green PhD,Dr S. Doshi BS, Dr Y.-M. Wang PhD,
Dr D. R. Mould PhD, FCP


Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies

Diane R. Mould , Bruce Green

Determination of Plasma Concentration Reference Ranges for Risperidone and Paliperidone

J Korell, B Green, B Remmerie, A Vermeulen


Optimizing Antipsychotic Patient Management Using Population Pharmacokinetic Models and Point-of-Care Testing

B Green,  J Korell, B Remmerie, A Savitz, A Vermeulen


The Impact of Model-Misspecification on Model Based Personalised Dosing

David A. J. McDougall , Jennifer Martin, E. Geoffrey Playford, Bruce Green


Determination of a suitable voriconazole pharmacokinetic model for personalised dosing

David A. J. McDougall , Jennifer Martin, E. Geoffrey Playford, Bruce Green


Individualized Compared With Conventional Dosing of Enoxaparin

MA Barras, SB Duffull, JJ Atherton, B Green

FDA Clinical Pharmacology Guidance on Paediatrics

General Clinical Pharmacology Considerations for Pediatric Studies for Drugs and Biological Products


Clinical trial simulations – an essential tool in drug development

Alun Bedding, Graham Scott, Nigel Brayshaw, Louise Leong, Esteban Herrero-Martinez, Michael Looby, Peter Lloyd

MENU